Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on CYTK stock, giving a Buy rating yesterday.
Roanna Ruiz has given her Buy rating due to a combination of factors surrounding Cytokinetics’ recent developments and financial outlook. The company’s confidence in aficamten’s benefit-risk profile and its potential differentiated positioning upon approval plays a significant role in this positive outlook. The anticipated top-line results from the Phase 3 MAPLE study and the early completion of enrollment for the ACACIA study further bolster the company’s prospects, despite the recent PDUFA date extension and changes in ACACIA endpoints.
Additionally, Cytokinetics’ strong cash position, with approximately $1.1 billion in cash and equivalents, provides a financial runway that extends beyond the potential U.S. launch of aficamten in early 2026. Although there is expected near-term volatility due to regulatory delays and competitive pressures, the company’s strategic positioning in the HCM space and the potential for aficamten to become a significant product contribute to the Buy rating. The updated price target of $57 reflects these considerations, alongside adjusted revenue forecasts and launch timelines.
According to TipRanks, Ruiz is an analyst with an average return of -12.6% and a 33.94% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and United Therapeutics.
In another report released yesterday, Citizens JMP also reiterated a Buy rating on the stock with a $78.00 price target.